Inflarx Nv Stock Investor Sentiment

IFRX Stock  USD 2.33  0.22  8.63%   
Slightly above 60% of InflaRx NV's investor base is looking to short. The analysis of the overall investor sentiment regarding InflaRx NV suggests that many traders are alarmed. InflaRx NV's investing sentiment can be driven by a variety of factors including economic data, InflaRx NV's earnings reports, geopolitical events, and overall market trends.
  

InflaRx NV Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards InflaRx NV can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at news.google.com         
InflaRx Announces Positive Topline Results from the Single Ascending Dose Phase I Study with C5aR I ...
Google News at Macroaxis
over a year ago at marketwatch.com         
InflaRx Sees Positive Topline Results in INF904 Trial
marketwatch News
over a year ago at benzinga.com         
InflaRx Announces Positive Topline Results from the Single Ascending Dose Phase I Study with C5aR In...
benzinga news
over a year ago at finance.yahoo.com         
InflaRx Announces Positive Topline Results from the Single Ascending Dose Phase I Study with C5aR In...
Yahoo News
over a year ago at news.google.com         
Vasculitis Treatment Market 2023 Industry Growth, Companies Profile, Competitive Landscape and Key R...
Google News at Macroaxis
over a year ago at news.google.com         
InflaRx Small German Company Targeting A Rare Indication ... - Seeking Alpha
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
InflaRxs Buy Rating Reiterated at HC Wainwright
news
over a year ago at news.google.com         
InflaRx Skyrockets 110 percent in Six Months Heres Why - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Biotech Stock Roundup FGEN Down on Study Failure, BMY Drugs Label Expansion More - Zacks Investment ...
Google News at Macroaxis
over a year ago at seekingalpha.com         
EU regulators accept InflaRX vilobelimab application for review
seekingalpha News
over a year ago at finance.yahoo.com         
InflaRxs Marketing Authorization Application for Vilobelimab for Treatment of Critically Ill COVID-1...
Yahoo News
over a year ago at globenewswire.com         
InflaRxs Marketing Authorization Application for Vilobelimab for Treatment of Critically Ill COVID-1...
Macroaxis News: globenewswire.com
over a year ago at benzinga.com         
InflaRxs Marketing Authorization Application for Vilobelimab for Treatment of Critically Ill COVID-1...
benzinga news
over a year ago at simplywall.st         
InflaRx Is In A Good Position To Deliver On Growth Plans
Simply Wall St News at Macroaxis
over a year ago at news.google.com         
Where Does Inflarx NV Stock Fall in the Biotechnology Field After It Is Lower By -4.38 percent This ...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about InflaRx NV that are available to investors today. That information is available publicly through InflaRx media outlets and privately through word of mouth or via InflaRx internal channels. However, regardless of the origin, that massive amount of InflaRx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of InflaRx NV news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of InflaRx NV relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to InflaRx NV's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive InflaRx NV alpha.

InflaRx NV Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
InflaRx Short Interest Update
10/14/2024
2
InflaRx N.V. Reports Q3 Loss, Tops Revenue Estimates
11/08/2024
3
Lucid Capital sets Inflarx NV Buy stock rating on clinical trial potential
11/19/2024
4
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
12/20/2024
5
InflaRx Announces Participation in January Events in San Francisco
01/07/2025

Additional Tools for InflaRx Stock Analysis

When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.